|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
GC unveils P1 results for hepatitis B treatment
By Lee Han-soo
Published 2019.02.26 16:07
Updated 2019.02.26 16:07
comments 0
글씨키우기
글씨줄이기
Send Mail
Print
페이스북
트위터
구글
카카오스토리
GC said Monday that it has presented the phase 1 clinical trial results for GC1102, a new recombinant hepatitis B immunoglobulin, at the annual Asian Pacific Association for The Study of the Liver Conference.
Professor Lee Hae-won presents the phase 1 clinical trial for Hepabig-gene, at the 2019 Asian Pacific Association for the Study of the Liver Conference held in the Philippines.
GC1102, also known as Hepabig-gene, employs immunoglobulins made from genetic recombination technology as its primary treatment source and prevents the recurrence of hepatitis B virus infection following liver transplantation.
In the presentation, the company unveiled a result confirming the efficacy and safety of the drug against chronic hepatitis B patients.
In particular, there were no severe side effects when the company increased the dose of Hepabig-gene to a maximum, and the dose and frequency of administration. The company also confirmed that the treatment could significantly reduce hepatitis B surface antigen.
“Participants in the meeting were interested in the possibility of improving the treatment level of chronic hepatitis B with Hepabig-gene,” said Professor Lee Hae-won of the department of gastroenterology at Severance Hospital who presented the study. “We will specify a method of maximizing treatment through a combination treatment of Hepabig-gene and antiviral drug during the phase 2 clinical trial.”
The company reportedly had administered the first dose of GC1102 to a patient participating in the phase 2a clinical trial on Feb. 15. |
|
发表于 2019-2-28 17:31
